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Abstract 
Background: The gastric cancer is one of the most common and mortal cancer worldwide. The initial asymptomatic 
development and further nonspecific symptoms result in diagnosis at the advanced stage with poor prognosis. Yet, 
no clinically useful biomarkers are available for this malignancy, and invasive gastrointestinal endoscopy remains the 
only reliable option at the moment. Hence, there is a need for discovery of clinically useful noninvasive diagnostic 
and/or prognostic tool as an alternative (or complement) for current diagnostic tools. Here we aimed to search for 
serum proteins characteristic for local and invasive gastric cancer.
Methods: Pre‑treatment blood samples were collected from patients with diagnosed gastric adenocarcinoma at the 
different stage of disease: 35 patients with locally advanced cancer and 18 patients with metastatic cancer; 50 healthy 
donors were also included as a control group. The low‑molecular‑weight fraction of serum proteome (i.e., endog‑
enous peptidome) was profiled by the MALDI‑ToF mass spectrometry, and the whole proteome components were 
identified and quantified by the LC–MS/MS shotgun approach.
Results: Multicomponent peptidome signatures were revealed that allowed good discrimination between healthy 
controls and cancer patients, as well as between patients with locally advanced and metastatic cancer. Moreover, 
a LC–MS/MS approach revealed 49 serum proteins with different abundances between healthy donors and cancer 
patients (predominantly proteins associated with inflammation and acute phase response). Furthermore, 19 serum 
proteins with different abundances between patients with locally advanced and metastatic cancer were identi‑
fied (including proteins associated with cytokine/chemokine response and metabolism of nucleic acids). However, 
neither peptidome profiling nor shotgun proteomics approach allowed detecting serum components discriminating 
between two subgroups of patients with local disease who either developed or did not develop metastases during 
follow‑up.
Conclusions: The molecular differences between locally advanced and metastatic gastric cancer, as well as more 
obvious differences between healthy individuals and cancer patients, have marked reflection at the level of serum 
proteome. However, we have no evidence that features of pre‑treatment serum proteome could predict a risk of can‑
cer dissemination in patients treated due to local disease. Nevertheless, presented data confirmed potential applica‑
bility of a serum proteome signature‑based biomarker in diagnostics of gastric cancer.
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Background
Gastric cancer is the fourth most common cancer and the 
second leading cause of cancer-related death worldwide. 
This cancer especially afflicts populations of East Asia, 
Eastern Europe, and parts of Central and South America, 
and the morbidity rate is twice higher for men than for 
women [1]. The malignancy is associated with nonspe-
cific symptoms or even asymptomatic development in its 
early stages, which often results in diagnosis at advanced 
stages. Stage of gastric cancer strongly correlates with 
poor prognosis. According to the National Cancer Data 
Base report, 5-year survival rate for stage IA was 78  % 
and it dropped substantially at each stage to about 7  % 
for patients diagnosed with stage IIIB or stage IV disease 
[2]. Thus, early diagnosis of gastric cancer might radically 
increase efficacy of treatment and improve prognosis for 
this fatal illness. At present the most efficient diagnostic 
tool for detection of gastric cancer remains a gastrointes-
tinal endoscopy, yet this invasive technique is not suit-
able for large-scale screening. Unfortunately, there is no 
alternative non-invasive biomarkers available, because 
the commonly used gastrointestinal tumor markers 
like CEA, CA 19-9 or CA 72-4 are insufficient for early 
diagnosis of this cancer due to their low sensitivity and 
specificity (20–30  %) [3–5]. Majority of gastric cancer 
cases (above 90  %) are classified as adenocarcinomas. 
More recently four molecular subtypes of gastric adeno-
carcinoma were distinguished based on genomic profil-
ing delivered thanks to the Cancer Genome Atlas project 
[6]. However, the knowledge on molecular heterogeneity 
and biology of this cancer, including its development and 
mechanisms of progression, remains rather limited yet. 
Hence, an urgent need for identification of clinically rel-
evant biomarkers relates not only the early diagnosis but 
also prognosis and prediction of treatment outcome.
Clinical proteomics is an important approach to dis-
covery of biomarkers of gastric cancer [7]. It is generally 
accepted that blood proteome is a promising source of 
novel biomarkers of this cancer, including particularly 
valuable markers for early detection of the disease and 
monitoring of response to the treatment [8]. Mass spec-
trometry-based profiling of the low-molecular-weight 
fraction of serum proteome, so called endogenous pepti-
dome, revealed multi-peptide signatures with potential 
applicability in classification and diagnosis of different 
cancer types [9–13]. A few works have been published 
that explored MALDI/SELDI-based profiling of serum/
plasma petidome for diagnosis of gastric cancer, which 
proposed peptide signatures that allowed discriminating 
healthy donors and patients with gastric cancer, or signa-
tures associated with a course of a disease [14–22]. Several 
components of such signatures were further identified as 
fragments of KNG1 [18], APOC1 and APOA2 [19], SAA 
[20], TBB5 and TYB4 [22] or FIBA [23, 24]. More recently, 
a panel of biomarkers composed of serum proteins pre-
selected based on preclinical mouse model (afamin, 
clusterin, VDBP and haptoglobin) has been validated to 
discriminate between gastric cancer patients and patient 
with benign gastric diseases [25]. Nevertheless, none of 
proposed serum proteome signatures of gastric cancer has 
been widely accepted and applied in clinical practice yet.
Here we aimed to characterize proteome features of 
pre-treatment serum associated with risk of metastasis 
of gastric cancer. Two types of proteomic analyses were 
performed: (1) the low-molecular-weight fraction of 
serum proteome was profiled by the MALDI-ToF mass 
spectrometry, (2) the whole proteome components were 
identified and quantified by LC–MS/MS after digestion 
with trypsin (a “shotgun proteomics” approach). Groups 
of previously untreated patients with locally advanced 
gastric cancer and metastatic disease were enrolled to 
this study (a matched group of healthy individuals was 
analyzed as a reference); such comprehensive proteomic 
analysis was performed in a group of Caucasians patients 
with gastric cancer for the first time. Serum proteome 
signature that differentiated between patients with locally 
advanced cancer and metastatic cancer was detected in 
this pilot study, yet features specific for patients with 
locally advanced disease at time of diagnosis who eventu-
ally developed metastases were not observed at this level.
Methods
Characteristics of patient groups
Fifty-three patients with previously untreated biopsy-
proven gastric adenocarcinoma were qualified into this 
study: 35 patients with locally advanced cancer, includ-
ing 16 patients with metastasis developed during therapy 
or follow-up and 19 patients with no detected metastasis 
during follow-up, and 18 patients with metastatic can-
cer. The latter group consisted of four patients with dis-
tant spread to single organ and 14 patients with spread 
to multiple organs; involved organs included perito-
neum (13 cases), liver (eight cases), lung (three cases), 
other locations (eight cases). In general, inclusion criteria 
involved: Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2, age 20–85 years, serum cre-
atinine level <1.5 mg/dl, serum bilirubin level <2.0 mg/dl, 
a granulocyte count >1500  cells/μl and a platelet count 
>100,000 cells/μl, while exclusion criteria involved: previ-
ous malignancy, previous surgery, radiotherapy or chem-
otherapy. The pretreatment staging based on physical 
examination, esophagogastroscopy with biopsies, CT of 
the abdomen and chest examination by X-ray or CT. Fifty 
sex- and age-matched disease-free donors were included 
as a control group. All study participants were Cauca-
sians (~65 % men) with the age at the range 34–74 years. 
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Table 1 shows more detailed information about analyzed 
groups. The study was approved by the appropriate Eth-
ics Committee, and all persons who were taking part in 
this study provided informed consent indicating their 
conscious and voluntary participation.
Preparation of serum samples
Pre-treatment blood was collected into a 5 ml Vacutainer 
Tube (Becton–Dickinson), incubated for 30 min at room 
temperature to allow clotting and then centrifuged at 
1000g for 10 min to remove the clot. The serum was ali-
quoted and stored at −70 °C until use.
Profiling of the low‑molecular‑weight fraction of serum 
proteome
Before analysis samples were diluted 1:5 with buffer 
containing 20 % acetonitrile (ACN) and 25 mM ammo-
nium bicarbonate, and then filtered by centrifugation 
through Amicon Ultra units (50 kDa cut-off) for remov-
ing the abundant high-molecular weight proteins, par-
ticularly albumin. Immediately before analysis samples 
were desalted and concentrated by loading onto ZipTip 
C18 microcolumns (EMD Millipore), and then eluted 
with 1 μl of matrix solution (saturated solution of alpha-
cyano-4-hydroxy-cinnamic acid in 30  % ACN/H2O and 
0.1  % TFA) directly onto the 800  μm AnchorChip™ 
(Bruker Daltonics) plate. The analysis was done by using 
an UltrafleXtreme MALDI-ToF mass spectrometer 
(Bruker Daltonics); the analyzer worked in the linear 
mode, and positive ions were recorded in the mass range 
between 1000 and 12,000 Da. The samples were spotted 
in duplicate and for each spot two spectra were acquired. 
Mass calibration was performed after every four samples 
using Protein Calibration Standard I (Bruker Daltonics). 
Randomization in blocks was used in spectra registration 
to avoid a possible batch effect. Afterwards the raw data 
was exported to TXT files and the spectral components 
were preprocessed using bioinformatics algorithms cre-
ated in our group, which included alignment, detection 
and removal of outlier profiles by Dixon’s Q test (single 
spectra were removed from about 5 % of samples), aver-
aging of technical repeats, baseline removal and normali-
zation of the total ion current. The spectra smoothing, 
peak picking, binning and statistical analysis were per-
formed using Spectrolyzer software (version 1.0.21.3590, 
MedicWave).
LC–MS/MS analysis of serum proteome components
Serum samples were reduced with 5  mM dithiothrei-
tol for 5  min at 95  °C, then alkylated with 10  mM 
Table 1 Characteristics of donor groups enrolled into the study
Group of patients with locally advanced cancer at time of diagnosis were further split into subgroup where either no spread (control) or consecutive cancer 
dissemination/spread (distant metastasis) was detected
Group/parameter Healthy control Cancer patients  
(all cases)
Patients with locally advanced cancer Patients 
with metastatic 
cancerNo spread Spread
Number (n) 50 53 19 16 18
Sex (M/F) 30/20 37/16 12/7 13/3 12/6
Age (years) 28–60 (median 50) 34–74 (median 59) 36–70 (median 59) 34–73 (median 58) 35–74 (median 60)
Tumor location
 Upper third – 15 (28 %) 3 (16 %) 6 (37 %) 6 (33 %)
 Middle third – 31 (59 %) 13 (68 %) 9 (57 %) 9 (50 %)
 Lower third – 7 (13 %) 3 (16 %) 1 (6 %) 3 (17 %)
Histological grade
 G1–G2 – 16 (30 %) 10 (53 %) 3 (19 %) 3 (17 %)
 G3 – 29 (55 %) 8 (42 %) 11 (69 %) 10 (56 %)
 Not specified – 8 (15 %) 1 (5 %) 2 (12 %) 5 (27 %)
Primary tumor
 cT1–T3 – 50 (94 %) 19 (100 %) 16 (100 %) 15 (83 %)
 cT4 – 3 (6 %) 0 (0 %) 0 (0 %) 3 (17 %)
Lymph node
 cN0 – 20 (38 %) 13 (68 %) 5 (31 %) 2 (11 %)
 cN1–N3 – 33 (62 %) 6 (32 %) 11 (69 %) 16 (89 %)
Metastasis (initial)
 cM0 – 35 (66 %) 19 (100 %) 16 (100 %) 0 (0 %)
 cM1 – 18 (34 %) 0 (0 %) 0 (0 %) 18 (100 %)
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iodoacetamide for 20  min in darkness at room tem-
perature, and afterwards digested overnight at 37  °C 
with trypsin (Promega). The analysis was performed on 
Dionex UltiMate 3000 RSLC nanoLC System connected 
to Q Exactive Orbitrap mass spectrometer (Thermo 
Fisher Scientific); each sample was analyzed separately. 
Tryptic peptides (2.5  µg of peptides) were separated on 
reverse phase Acclaim PepMap RSLC nanoViper C18 col-
umn (75 µm × 25 cm, 2 µm granulation) using the ace-
tonitrile gradient (from 4 to 60 %, in 0.1 % formic acid) 
at 30  °C and a flow rate of 250  nL/min (for 230  min). 
The spectrometer was operating in the data-dependent 
MS/MS mode with survey scans acquired at a resolu-
tion of 70,000 at m/z 200 Da in MS mode and 17,500 at 
m/z 200 Da in MS2 mode, respectively. The spectra were 
recorded in the scan m/z range 300–2000 in the positive 
ion mode. Higher energy collisional dissociation (HCD) 
ion fragmentation was performed with normalized col-
lision energies set to 25. Protein identification was 
performed using Swiss-Prot human database with a pre-
cision tolerance 10 ppm for peptide masses and 0.05 Da 
for fragment ion masses. The abundances of identi-
fied proteins were estimated using MaxQuant 1.4.1.1 
software.
Statistical and bioinformatics analyses
For each component of MALDI mass profiles the com-
parison between groups of donors was performed using 
the Student’s t test after logarithmic transformation of 
data. Multi-component classifiers were built and tested 
with the SVM-based approach using Spectrolyzer soft-
ware (version 1.0.21.3590, MedicWave). Significance 
of differences in abundances of proteins quantified by 
LC–MS/MS were assessed using the t test or the Mann–
Whitney test depending on normality of data (type of 
distribution was estimated using the Shapiro–Wilk test, 
the Lilliefors test and the F test for homogeneity of vari-
ances), and the Nemenyi test for pairwise comparisons. 
In general, p =  0.05 was selected as a statistical signifi-
cance threshold except for MALDI profiling where the 
Bonferroni correction for multiple testing was applied. 
The Empirical Proteomic Ontology Knowledge Base 
(EPO-KB), which annotates registered m/z values to 
known peptide/proteins [26], was employed to assign 
hypothetical identification of the spectra components 
(0.5  % mass accuracy limit was allowed). List of genes 
corresponding to identified proteins was annotated at 
GO terms using gProfiler (http://biit.cs.ut.ee/gprofiler/); 
the significance of the term over-representation was 
assessed using the hypergeometric distribution test. In 
order to visualize functional relationships between iden-
tified proteins corresponding genes were annotated at 
the GeneMANIA Cytoscape plugin for pathway interac-
tion networks (http://pages.genemania.org/plugin/).
Results
Mass profiles of the serum endogenous peptidome (the 
low-molecular-weight fraction of serum proteome) were 
characterized by MALDI-ToF spectrometry in the whole 
group of 53 patients with gastric cancer and 50 matched 
healthy donors. This analysis allowed us to asses overall 
degree of differences and similarities between subgroups 
of analyzed individuals. In general, 255 spectral compo-
nents (peptide ions) were distinguished in the analyzed 
mass range (Fig. 1a), and abundances of 101 components 
revealed statistically significant variation among com-
pared groups (after the Bonferroni correction against 
multiple testing). Table  2 presents numbers of serum 
peptidome components that differentiated particular 
groups of donors. The major differences in abundances 
of specific serum components were observed between 
cancer patients and healthy donors (about 39  % of reg-
istered components reveled statistically significant dif-
ferences). Large differences were also observed between 
patients with locally advanced cancer (all cases) and 
patients with metastatic cancer (about 9 % of registered 
components reveled statistically significant differences); 
this is noteworthy that similar numbers of differentiat-
ing components were observed when patients with meta-
static cancer were compared with both subgroups with 
local disease separately (i.e., group where distant spread 
of cancer was detected during follow-up and group 
without evidence of disease). Coherently, well perform-
ing classifiers could be built based on features of serum 
peptidome that separated compared groups of healthy 
donors and patients with locally advanced or meta-
static cancer (the AUC measure for SVM-based clas-
sifier was above 90 % in each case). In marked contrast, 
no statistically significant difference was detected when 
two subgroups of patients with locally advanced cancer 
(who either developed or not developed metastasis dur-
ing follow-up) were compared (the AUC of SVM-based 
classifier was below 50 %). Figure 1b presents examples of 
serum peptidome components with significantly different 
abundances among compared groups. This is notewor-
thy that among petidome components that differentiated 
both healthy controls from cancer patients and patients 
with locally advanced cancer from patients with meta-
static disease there were several components that puta-
tively corresponded to fragments of fibrinopeptide A 
(FIBA). These included components with registered m/z 
value 1088.7, 5903.5 and 5916.6  Da significantly down-
regulated in serum of cancer patients, and components 
1469.9 and 1626.0 Da with markedly higher abundances 
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in serum of patients with metastatic disease than in 
patients with locally advanced cancer (see Fig. 1b; Addi-
tional file 1: Table S1). We concluded that molecular dif-
ferences between locally advanced and metastatic gastric 
cancer (as well as differences between healthy individuals 
and patients with gastric cancer in general) have reflec-
tion at the level of serum peptidome. However, features 
of peptidome of pre-treatment serum could be unlikely 
applied for prognosis of the disease spread during/after 
the treatment.
In the second step we selected samples of 12 healthy 
donors and ten patients from each cancer subgroup to 
secure similar age (medians about 56 years) and propor-
tion of sexes (ca. 80 % of males) in compared subgroups. 
These samples were used for further analyses based on 
the shotgun LC–MS/MS approach. In general, about 
450 proteins were identified in analyzed serum samples. 
Levels of 234 serum proteins were quantified in sam-
ples collected from each of 42 individuals, including 129 
unique serum proteins not related to immunoglobulins 
(105 immunoglobulins and Ig-related proteins, as well 
as putative uncharacterized proteins, were excluded 
from further analyses); complete data are presented in 
the Additional file 1: Table S2. There were 49 serum pro-
teins with abundances different between healthy donors 
and patients with gastric cancer (p value <0.05; estimated 
FDR value = 13 %): 41 proteins were upregulated while 
eight proteins were downregulated in blood of cancer 
patients (proteins listed in Table  3; examples in Fig.  2). 
This is noteworthy that similar patterns of cancer-related 
upregulation or downregulation of serum proteins was 
observed in all there subgroups of cancer patients (even 
though smaller size of analyzed groups might reduce 
statistical significance of differences; see Additional 
file 1: Table S3). Moreover, there were 19 serum proteins 
with abundances different between patients with locally 
advanced and metastatic cancer (p value <0.05; estimated 
FDR value = 34 %): three proteins were upregulated while 
16 proteins were downregulated in blood of patients with 
metastatic disease. This is noteworthy that abundances of 
C-reactive protein and angiogenin generally upregulated 
in cancers samples further increased in metastatic sam-
ples, while abundances of carbonic anhydrase 1 gener-
ally downregulated in cancer samples further decreased 
Fig. 1 Profile of endogenous serum peptidome of patients with gas‑
tric cancer. a Average mass spectrum in the range of 1000–10,000 Da. 
b Examples of serum peptidome components, which abundances 
were different between samples from healthy controls and different 
groups of patients with stomach cancer. Boxplots show minimum, 
lower quartile, median, upper quartile, maximum values, and outliers; 
asterisks marked significant differences (p < 0.05 with the Bonferroni 
correction)
Table 2 Numbers of serum peptidome components with abundances different between compared groups of individuals
Shown are numbers of differentiating components that reached threshold of statistical significance p = 0.05 (with corresponding FDR estimation) or threshold 
strengthened with the Bonferroni correction, and power of SVM classifier built of peptidome components (characterized by the AUC value)
Groups/differences Control vs.  
cancer (all cases)
Locally advanced vs. 
metastatic cancer
Local/no spread vs. 
metastatic cancer
Local/spread vs.  
metastatic cancer
Local/no spread vs. 
local/spread cancer
n 50 vs. 53 35 vs. 18 19 vs. 18 16 vs. 18 19 vs. 16
p < 0.05 182 88 74 75 11
FDR 7 % 14 % 17 % 17 % 100 %
p < 0.05/Bonferroni 101 23 11 16 0
AUC (SVM) 0.94 0.91 0.92 0.97 0.48
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Table 3 Differentiating serum proteins
Protein name Protein full name Gene name Control/cancer Local/metastatic
Ratio p value Ratio p value
A1AG1 Alpha‑1‑acid glycoprotein 1 ORM1 0.67 0.0008 1.00 0.5824
A1AG2 Alpha‑1‑acid glycoprotein 2 ORM2 0.68 0.0006 1.00 0.7414
A1AT Alpha‑1‑antitrypsin SERPINA1 0.50 <0.0001 1.03 0.6441
A1BG Alpha‑1B‑glycoprotein A1BG 0.76 0.0072 1.04 0.5824
A2GL Leucine‑rich alpha‑2‑glycoprotein LRG1 0.46 0.0016 0.80 0.4414
AACT Alpha‑1‑antichymotrypsin SERPINA3 0.54 0.0007 0.97 0.9124
ADIPO Adiponectin ADIPOQ 0.41 0.0092 1.60 0.3442
AFAM Afamin AFM 1.30 0.0355 1.06 0.5824
ANGI Angiogenin ANG 0.30 0.0465 0.24 0.0294
APOA1 Apolipoprotein A‑I APOA1 0.47 <0.0001 1.31 0.0235
APOC1 Apolipoprotein C‑I APOC1 0.25 <0.0001 1.52 0.1183
APOC3 Apolipoprotein C‑III APOC3 1.82 0.0108 1.20 0.5824
APOE Apolipoprotein E APOE 0.62 0.0040 1.01 0.6441
APOF Apolipoprotein F APOF 0.64 0.0085 0.80 0.5235
APOM Apolipoprotein M APOM 0.92 0.4275 1.51 0.0263
C1S Complement C1s subcomponent C1S 0.70 0.0016 1.22 0.0748
CAH1 Carbonic anhydrase 1 CA1 2.96 0.0173 2.41 0.0143
CBG Corticosteroid‑binding globulin SERPINA6 0.53 0.0117 1.08 0.7749
CD14 Monocyte antigen CD14 CD14 0.56 0.0033 1.21 0.1658
CERU Ceruloplasmin CP 0.67 0.0013 1.05 0.6129
CFAB Complement factor B CFB 0.61 0.0006 1.11 0.6441
CO2 Complement C2 C2 0.64 0.0475 1.57 0.0679
CO4A Complement C4‑A C4A 0.87 0.0435 0.94 0.7749
CO4B Complement C4‑B C4B 0.73 0.0127 0.99 0.5526
CO5 Complement C5 C5 0.77 0.0085 0.91 0.8776
CO6 Complement component C6 C6 0.64 0.0013 0.97 0.8431
CO8G Complement component C8 gamma C8G 0.66 0.0137 1.12 0.4679
CO9 Complement component C9 C9 0.42 <0.0001 0.93 0.9124
CRP C‑reactive protein CRP <0.01 0.0389 0.15 0.0414
CXCL7 Platelet basic protein PPBP 0.83 0.1516 1.53 0.0030
FETUA Alpha‑2‑HS‑glycoprotein AHSG 0.90 0.3095 1.34 0.0068
FHR1 Complement factor H‑related prot. 1 CFHR1 0.66 0.0725 1.30 0.0366
GPX3 Glutathione peroxidase 3 GPX3 0.92 0.6065 1.47 0.0453
HBA Hemoglobin subunit alpha HBA1 2.02 0.0016 1.18 0.5824
HBB Hemoglobin subunit beta HBB 2.26 0.0005 1.11 0.6441
HBD Hemoglobin subunit delta HBD 4.59 0.0030 1.02 0.9608
HEMO Hemopexin HPX 0.77 0.0061 1.00 0.9124
HGFA Hepatocyte growth factor activator HGFAC 1.57 0.0868 1.74 0.0366
HGFL Hepatocyte growth factor‑like prot. MST1 1.40 0.4048 3.28 0.0156
HPT Haptoglobin HP 0.68 0.0014 1.02 0.7749
IC1 Plasma protease C1 inhibitor SERPING1 3.36 0.0001 0.21 0.0030
ITIH1 Inter‑alpha‑trypsin inhib. heavy ch. 1 ITIH1 0.77 0.0465 1.06 0.2099
ITIH3 Inter‑alpha‑trypsin inhib. heavy ch. 3 ITIH3 0.45 0.0001 1.05 0.4414
LBP Lipopolysaccharide‑binding protein LBP 0.42 0.0004 0.78 0.7084
LG3BP Galectin‑3‑binding protein LGALS3BP 0.23 0.0006 1.29 0.8776
PGRP2 N‑acetylmuramoyl‑l‑alanine amidase PGLYRP2 0.82 0.0497 1.15 0.4157
PLF4 Platelet factor 4 PF4 1.00 0.9667 1.41 0.0366
PON1 Serum paraoxonase/arylesterase 1 PON1 0.88 0.4606 1.42 0.0442
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in metastatic samples (Table  3). Furthermore, patterns 
of differences between samples from patients with met-
astatic cancer and all patients with local disease were 
retained when two smaller subgroups of patients with 
locally advanced cancer were pairwise compared with 
metastatic cancer (see Additional file 1: Table S4). On the 
other hand, abundance of only one protein (antithrom-
bin-3) showed statistically significant difference when 
both subgroups of patients with locally advanced can-
cer were compared (abundance of this protein was the 
highest in group of patients with local disease who do 
not spread during follow-up). We concluded that multi-
protein signature could be identified for classification of 
pre-treatment serum samples of gastric cancer patients, 
who suffered from either locally advanced or metastatic 
disease. However, features of serum proteome could not 
distinguish patients with local disease that spread during 
follow-up after the treatment. 
To identify molecular processes associated with serum 
proteins characteristic for gastric cancer, corresponding 
genes were annotated at the Gene Ontology database 
(Ig-related proteins were excluded from the analysis) 
(see Additional file 1: Table S5). There were 59 over-rep-
resented GO terms associated with proteins differentiat-
ing cancer patients from healthy donors. Among them 
dominated terms associated with different aspects of 
defense, inflammation and immune response (23 terms). 
Network of functional interactions was built based on 
the GeneMANIA Cytoscape tool to illustrate confirmed 
interactions between serum proteins characteristic for 
cancer patients. Figure  3 shows such network and its 
overlap with functional group of proteins associated with 
inflammatory/acute phase response and/or complement 
activation (CRP, C1S, CO2, CO4A, CO5, CO6, CO8G, 
CO9, CFAB, PROP). Moreover, there were 57 over-rep-
resented GO terms associated with proteins differentiat-
ing patients with locally advanced and metastatic disease. 
Among them dominated terms associated with metabo-
lism of phosphorus and nucleic acids (16 terms) and with 
response to cytokines/chemokines and leukocyte migra-
tion (13 terms) (see Additional file 1: Table S6). We con-
cluded that serum proteome signature that differentiated 
gastric cancer patients from healthy donors consisted of 
proteins primarily involved in cancer-type-nonspecific 
processes associated with inflammation and immune 
response (even though Ig-related proteins were excluded 
from analysis). On the other hand, serum proteome sig-
nature characteristic for metastatic cancer consisted 
of proteins primarily involved in cytokine/chemokine 
response and/or proliferation.
Discussion
The last decade has abounded in the publications that 
reported the MALDI/SELDI-based profiling of the serum 
peptidome as a promising tool for the effective identifi-
cation of gastric cancer patients [14–22]. Four different 
diagnostic classifiers were built on the basis of tri-peptide 
combination by Ebert et al. [14] (m/z 3946, 3503, 15,958), 
Su et al. [16] (m/z 1468, 3935, 7560), Liu et al. [19] (m/z 
5906.4, 6632.9, 8704.3) and Fan et  al. [22] (m/z 1867, 
2701, 2094). Although the discriminatory peaks were 
not consistent among those studies, probably because 
of the diverse methodology of sample preparation (espe-
cially highly abundant proteins removal), measurement 
and/or data processing [13], there were some common 
features of proposed signatures. For example, the m/z 
Showed are proteins, which abundances were different between samples from healthy controls and patients with stomach cancer (all cases), or between patients with 
locally advanced and metastatic cancer. Differences (ratios of the mean abundances) that passed the threshold of statistical significance (p < 0.05) are marked in italics 
characters
Table 3 continued
Protein name Protein full name Gene name Control/cancer Local/metastatic
Ratio p value Ratio p value
PROP Properdin CFP 1.45 0.0028 1.11 0.9825
PROZ Vitamin K‑dependent protein Z PROZ 0.93 0.6864 2.08 0.0186
S10A9 Protein S100‑A9 S100A9 0.11 0.0054 0.74 0.2526
SAA1 Serum amyloid A‑1 protein SAA1 0.04 0.0407 0.49 0.2099
SAA2 Serum amyloid A‑2 protein SAA2 <0.01 0.0389 0.44 0.3069
SEPP1 Selenoprotein P SEPP1 1.72 0.1292 1.52 0.0186
SHBG Sex hormone‑binding globulin SHBG 0.20 0.0329 0.67 0.1968
THBG Thyroxine‑binding globulin SERPINA7 0.70 0.0309 0.80 0.8088
TSP1 Thrombospondin‑1 THBS1 0.74 0.1363 1.49 0.0436
VTDB Vitamin D‑binding protein GC 0.81 0.0160 1.24 0.0235
VTNC Vitronectin VTN 0.82 0.0394 1.15 0.1083
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peak at 1466–1468  Da identified as fibrinopeptide A 
(FIBA) was reported as a candidate biomarker in three 
reports [16, 23, 24]. Moreover, increased level of another 
fragment of FIBA (approx. weight 5904–5906  Da) was 
observed in serum of patients with gastric cancer [19], 
but also in serum of patients with ovarian, hepatocellu-
lar and urothelial cancers [27–29]. In our study we have 
detected over 100 components of serum peptidome that 
differentiate compared groups of gastric cancer patients 
and healthy volunteers. This included several compo-
nents that putatively corresponded to fragments of FIBA, 
exemplified by 1469 and 5904  Da components upregu-
lated in blood of patients with metastatic cancer. Thus, 
our results clearly confirmed and extended previous 
reports indicating that multipeptide signatures based on 
features of endogenous serum peptidome could be used 
for classification of patients with gastric cancer and dif-
ferentiation of patients with metastatic disease.
In the second part of our study serum samples were fur-
ther analyzed using the shotgun LC–MS/MS approach, 
which is currently the gold standard for identification of 
proteins allowing label-free quantitation and providing 
Fig. 2 Examples of serum proteins that discriminated groups of donors. Boxplots show minimum, lower quartile, median, upper quartile and maxi‑
mum values; asterisks marked significant differences (p < 0.05)
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large coverage of sample’s proteome [30]. Among serum 
proteins with abundances significantly different between 
healthy individuals and patients with gastric cancer dom-
inated those associated with immunity, inflammation and 
acute phase response, even though immunoglobulins 
were excluded from the analysis. Up-regulation of pro-
teins involved in immunity and inflammation is a typical 
picture of serum proteome of cancer patients, especially 
in advanced cases, and increased levels of proteins like 
C-reactive protein, haptoglobin or serum amyloid have 
been previously reported for many different types of 
cancer [31–35]. Most recently, iTRAQ-based approach 
has been used to identify serum proteins differentiat-
ing healthy controls and patients with gastric adeno-
carcinoma in a small sample of Asian population [36]. 
Upregulation of 48 proteins in samples of cancer patients 
was reported, that included several inflammation/acute 
phase-related proteins: A1AG1 (ORM1), A1AT (SER-
PINA1), AACT (SERPINA3), CO4B, CO9, HPT, ITIH4, 
LBP and SAA1, which upregulation was revealed also 
in our study. Moreover, other proteins revealed in both 
reports included upregulated A2GL (LRG1), ITIH3, 
ORM2 and SHGB, which collectively indicated very high 
conformity of serum proteome signature of gastric can-
cer that based on samples of unrelated Polish and India’s 
populations.
Moreover, our study revealed serum proteome com-
ponents with levels discriminating patients with locally 
advanced gastric adenocarcinoma and with metastatic 
disease. Proteins upregulated in serum of patients with 
metastatic disease included C-reactive protein and IC1 
(SERPING1), factors involved in immunity and inflam-
mation, and angiogenin, protein involved in angiogen-
esis. Other proteins differentially expressed in blood 
of patients with local and metastatic cancer included 
molecules associated with response to cytokines/
chemokines, leukocyte migration and blood coagu-
lation as well as factors associated with extracellular 
transport, and metabolism of phosphorus and nucleic 
acids. Elevated level of CEA and CA 19-9 was previ-
ously associated with increased risk of gastric cancer 
metastases. However, increased level of such “classical” 
markers has been observed only in case of 30–50 % of 
patients with disseminated disease [3–5], thus there 
is an obvious space for new proteomics-based mark-
ers of metastatic gastric cancer. Furthermore, several 
patients enrolled into the study were diagnosed with 
locally advanced cancer, yet in some cases the disease 
was spread and distant metastases were detected dur-
ing follow-up. However, comparison of pre-treatment 
serum samples collected in both subgroups of patients 
with local disease (who further either developed or did 
not distant metastases) revealed very few significant 
differences (similar results were delivered by LC–MS/
MS-based analysis of complete proteome and MALDI-
based profiling of endogenous peptidome). Hence, our 
data revealed serum proteome signature discriminat-
ing patients with locally advanced and metastatic gas-
tric adenocarcinoma. However, our study did not reveal 
serum proteome components that could be used for 
prediction of risk of metastasis in patients diagnosed 
with local cancer.
Fig. 3 Network of functional interaction between serum proteins associated with stomach cancer. Red and green circles represent proteins upregu‑
lated and downregulated, respectively, in samples from cancer patients; blue circles represent proteins with significantly different abundances in 
samples of patients with locally advanced and metastatic disease (black circles represent other quantified proteins involved in interactions)
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Conclusions
Significant differences between patients with gastric can-
cer and healthy individuals as well as between patients 
with locally advanced and metastatic cancer have been 
detected at the level of serum proteome in pre-treat-
ment blood samples. However, no evidence that features 
of pre-treatment serum proteome could predict a risk 
of cancer dissemination in patients treated due to local 
disease has been observed. Nevertheless, presented data 
confirmed potential applicability of biomarkers based 
on serum proteome signature in diagnostics of gastric 
cancer.
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